These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9126662)

  • 1. Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin.
    Muramatsu J; Kobayashi A; Hasegawa N; Yokouchi S
    Atherosclerosis; 1997 Apr; 130(1-2):179-82. PubMed ID: 9126662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simvastatin and pravastatin equally improve flow-mediated dilation in males with hypercholesterolemia.
    Sebestjen M; Boh M; Keber I
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):999-1003. PubMed ID: 12635468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of pravastatin on exercise electrocardiography test performance and cardiovascular mortality and morbidity in patients with hypercholesterolemia: Lipid Intervention Study in Kyoto.
    Sasaki S; Nakagawa M; Nakata T; Azuma A; Sawada S; Takeda K; Asayama J;
    Circ J; 2002 Jan; 66(1):47-52. PubMed ID: 11999665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middle-aged men free from cardiovascular disease.
    Bak AA; Huizer J; Leijten PA; Rila H; Grobbee DE
    J Intern Med; 1998 Nov; 244(5):371-8. PubMed ID: 9845852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins improve visual field alterations related to hypercholesterolemia.
    Alcalá A; Jansen S; Téllez T; Gómez-Huelgas R; Pérez O; Egido J; Farkouh ME
    Atherosclerosis; 2010 Apr; 209(2):510-4. PubMed ID: 19892351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pravastatin sodium, a new HMG-CoA reductase inhibitor.
    Raasch RH
    DICP; 1991 Apr; 25(4):388-94. PubMed ID: 1926908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pravastatin on erythrocyte rheological and biochemical properties in poorly controlled Type 2 diabetic patients.
    Miossec P; Zkhiri F; Pariès J; David-Dufilho M; Devynck MA; Valensi PE
    Diabet Med; 1999 May; 16(5):424-30. PubMed ID: 10342343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test.
    Saito Y; Goto Y; Nakaya N; Hata Y; Homma Y; Naito C; Hayashi H; Ito H; Yamamoto M; Takeuchi I
    Atherosclerosis; 1988 Aug; 72(2-3):205-11. PubMed ID: 3145746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia.
    Grigore L; Raselli S; Garlaschelli K; Redaelli L; Norata GD; Pirillo A; Catapano AL
    Eur J Clin Pharmacol; 2013 Mar; 69(3):341-6. PubMed ID: 22777149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic study of statin therapy and cholesterol reduction.
    Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
    JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.
    Glorioso N; Troffa C; Filigheddu F; Dettori F; Soro A; Parpaglia PP; Collatina S; Pahor M
    Hypertension; 1999 Dec; 34(6):1281-6. PubMed ID: 10601131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia.
    Strauss WE; Lapsley D; Gaziano JM
    Am Heart J; 1999 Mar; 137(3):458-62. PubMed ID: 10047626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial.
    Dupuis J; Tardif JC; Cernacek P; Théroux P
    Circulation; 1999 Jun; 99(25):3227-33. PubMed ID: 10385495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
    Richter WO; Jacob BG; Schwandt P
    Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE).
    Ito H; Ouchi Y; Ohashi Y; Saito Y; Ishikawa T; Nakamura H; Orimo H
    J Atheroscler Thromb; 2001; 8(2):33-44. PubMed ID: 11770708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Improvements in insulin sensitivity and inflammatory markers are induced by pravastatin in nondiabetic subjects with hypercholesterolemia.
    Lee WJ; Lee WL; Tang YJ; Liang KW; Chien YH; Tsou SS; Sheu WH
    Clin Chim Acta; 2008 Apr; 390(1-2):49-55. PubMed ID: 18201563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia.
    Egashira K; Hirooka Y; Kai H; Sugimachi M; Suzuki S; Inou T; Takeshita A
    Circulation; 1994 Jun; 89(6):2519-24. PubMed ID: 8205659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.
    Hunninghake DB; Knopp RH; Schonfeld G; Goldberg AC; Brown WV; Schaefer EJ; Margolis S; Dobs AS; Mellies MJ; Insull W
    Atherosclerosis; 1990 Nov; 85(1):81-9. PubMed ID: 2126437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.